ACE is attending this week’s American College of Rheumatology/Association of Rheumatology Health Professionals 2018 Annual Meeting, the largest international gathering of arthritis researchers, clinicians, academics, patient advocates and arthritis health professionals. Here are some of today’s highlights:
Improving osteoarthritis management
There are currently more than 4.4 million Canadians living with osteoarthritis (OA). Within a generation (in 30 years), more than 10 million (or one in four) Canadians are expected to have OA. A 2017 study, “Productivity costs of work loss associated with osteoarthritis in Canada from 2010 to 2013,” found the rising rates of OA will cost the Canadian economy an estimated $17.5 billion a year in lost productivity by 2031 as the disease forces greater numbers of people to stop working or work less.
ACE and other members of the Arthritis Alliance of Canada have helped raise awareness with health care policy makers that OA is the leading cause of disability in older adults. One of Canada’s leading osteoarthritis researchers, Dr. Gillian Hawker, Sir John and Lady Eaton Professor and Chair of Medicine, Faculty of Medicine, University of Toronto has stated: “the highest rates of OA are increasing fastest among young people (20-59 years), due largely to childhood obesity and knee injury. While effective therapies exist, the high prevalence of comorbidity in people with OA makes management challenging (as many of 90% of people with OA have at least one additional chronic condition – most often diabetes, heart disease and high blood pressure).” Continue reading →
JointHealth™ Education: Advanced Therapies for Inflammatory Arthritis
Arthritis Consumer Experts (ACE) is excited to announce the launch of its newest on-line patient education course: JointHealth™ Education Advanced Therapies for Inflammatory Arthritis. This three-lesson course is designed to help patients living with inflammatory arthritis identify when is the appropriate time to transition from conventional synthetic disease modifying medications (csDMARDs) to an advanced therapy, such as a targeted synthetic DMARD or biologic DMARD, and what key questions to ask about how they are taken and how they work in the body.
“JointHealth™ Education was inspired by many of ACE’s members living with an inflammatory arthritis who have told us they lack the knowledge and communications skills to have full, satisfying conversations with their rheumatologists on topics such as treatment options during their appointments. We want to ensure patients have the tools to understand when they need to start thinking about a therapy change. Patients like me often wait too long to make treatment plan adjustments, such as moving to an advanced therapy,” said Cheryl Koehn, Founder and President of Arthritis Consumer Experts.
“Canadian rheumatologists have been actively discussing and pursuing ways to improve communication between patients and rheumatologists in order to work together to set treatment goals and establish a treatment plan to achieve the best possible disease outcomes. JointHealth™ Education Advanced Therapies is a great course not just for patients, but also for rheumatologists – junior and senior, alike. We need to see our patient’s experiences, needs and goals through their eyes and words,” said Kam Shojania, MD, FRCPC, Clinical Professor and Head, Division of Rheumatology, University of British Columbia, and Medical Director of the Mary Pack Arthritis Program.
The JointHealth™ Education program provides current, evidence-informed lessons, quizzes and coaching videos through a secure, on-line classroom where “students” can learn from the comfort of their own home or over the work day lunch hour. The program helps prepare patients to appropriately frame their health concerns and questions with their health care provider. Upon successful completion of a course the patient “Graduate” receives a certificate indicating they have the knowledge and communication tips needed to successfully prepare for their medical visit, talk to their healthcare provider about setting treatment goals and making an overall plan, discuss specific treatments to manage and monitor their type of arthritis.
Ankylosing spondylitis (AS) is one of the most common types of inflammatory arthritis. It is estimated to affect up to 1 in 200 people.
Ankylosing spondylitis primarily affects the spine, but can also involve the hips, knees, shoulders, and rib cage. The most common symptom of AS is long-term back pain, along with spinal stiffness in the morning or after a long period of rest (this is the main reason why AS is often mis-diagnosed as ordinary “low back pain”).
Unlike in many other forms of arthritis where women are most affected, three out of four people diagnosed with ankylosing spondylitis are men. It tends to strike in the prime of life; while it can strike at any age, it is most common in people between ages 15 and 40. While it has no known cure, it is treatable; with the proper care, people who are diagnosed with AS can lead full, productive lives.
In Arthritis Consumer Experts’ (ACE) April JointHealth™ insight, we explore what “personalized and precision medicine” – the theme to this year’s Canadian Rheumatology Association Annual Meeting and Arthritis Health Professions Association Annual Meeting – means to arthritis patients and health care providers. To help you, we have prepared a curated guide to a selection of #CRArthritis interviews, outlining key points covered during the event.
Among the topics of interest to patients, the interviews provide information on:
Personalized and precision medicine
Spondyloarthritis and psoriatic arthritis – Advancements in diagnosis and therapy
Giant cell arteritis and vasculitis
Exercise as medicine
Medical marijuana and pain management
Improving access to and quality of arthritis care
New research on preventing rheumatoid arthritis
Communicating with your doctor
Teamwork and patient-centred care in arthritis Models of Care
All interviews can be accessed through YouTube, Twitter, and Facebook.
To turn on French subtitles, please adjust the YouTube settings for each interview.
To ensure a smooth live streaming experience, make sure you have a strong internet connection or cellular network if you are participating from your mobile devices. To ask questions during the event, email firstname.lastname@example.org
Please ensure your volume is adjusted appropriately to hear the broadcast.
Please take a few minutes to complete a short survey to help the Canadian Spondylitis Association help you.
A co-morbidity is not a side effect.
A focus of the Canadian Spondylitis Association (CSA) in 2018 will be on highlighting and educating members about co-morbidities that are associated with spondyloarthritis. The CSA are forming partnerships to bring you the education and support that you should have. Individuals are sometimes diagnosed because of a co-morbidity or by a professional outside of rheumatology. In some cases, diagnosis is delayed due to the complexities of spondyloarthritis and its many co-morbidities.
Stand-up to spondyloarthritis! Together we can make a difference. Please take a few minutes of your time to complete a short survey to help the CSA help you.
The CSA will be updating their website with information on co-morbidities and include articles in upcoming newsletters highlighting a co-morbidity.
S’il vous plaît, prenez quelques minutes afin de complétez ce court sondage pour aider l’Association Canadienne de Spondylarthrite à vous aider!
Une co-morbidité n’est pas un effet secondaire.
En 2018, l’ACS mettra l’accent sur la sensibilisation et l’éducation des membres sur les co-morbidités associées à la spondylarthrite. Nous formons des partenariats pour vous apporter l’éducation et le soutien dont vous avez besoin. Les individus sont parfois diagnostiqués à cause d’une co-morbidité ou par un professionnel de la santé autre que la rhumatologie. Dans certains cas, le diagnostic est retardé en raison de la complexité de la spondylarthrite et de ses nombreuses co-morbidités.
Tenez tête à la spondylarthrite! Ensemble nous pouvons faire la différence. Veuillez prendre quelques minutes de votre temps pour remplir un court sondagepour nous aider – à vous aider.
Nous mettrons à jour notre site Web avec des informations sur les co-morbidités et incluant des articles, dans les prochains bulletins d’informations mettant en évidence une co-morbidité.
From this year’s EULAR annual conference comes major news for people living with spondyloarthritis (SpA). Based on recommendations from a task force of European and North American patients, rheumatologists, dermatologists, and health professionals, new treat-to-target (T2T) guidelines for SpA were announced that emphasize the importance to set a target in shared decision making between a specialist and patient and carefully monitor the disease in order to improve a patient’s health outcome.
“The T2T recommendations are following the principle that you have to define a target you want to reach and adapt management to reach this target. This is independent of the treatment you use to reach the target,” said Professor Desiree van der Hejde, a professor at Leiden University Medical Centre in the Netherlands. Continue reading →
This forum will help patients with ankylosing spondylitis and psoriatic arthritis and their family. Register now for free! The Spondyloarthritis Research Consortium of Canada and the Canadian Spondylitis Association, in collaboration with The Arthritis Society, would like to invite you to register for free to the 2016 Spondyloarthritis Patient Forum. The forum aims to help patients living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) and their family. Light refreshments will be provided.
Here are the event details:
Date: Saturday, April 30, 2016 Location: Sheraton Vancouver Wall Centre, Junior Ballroom CD
1088 Burrard Street, Vancouver Time: 3:30pm-7:00pm Cost: Free
Please note pre-registration is required. Seats are limited. You can register: Continue reading →
AS Health Storylines is a self-care app for ankylosing spondylitis (AS) and associated spondyloarthritis diseases. It is developed in partnership with the Canadian Spondylitis Association, and is powered by the Health Storylines™ platform from Self Care Catalysts Inc. The Canadian Spondylitis Association is a national association to advocate for and support those living with ankylosing spondylitis, psoriatic arthritis, and associated spondyloarthritis diseases.
This app is created with input from people with AS so that the right health tools are available to you. The app allows you to record your symptoms, fatigue levels, moods, and more. Choose what you want to track to build your own summary – “My Storylines” – to learn more about your health, and to share – safely and securely – with your doctor about what happened between visits.
The following health tools in the app will help you better manage and monitor your AS or associated spondyloarthritis disease: Continue reading →